Discount And Rebates Fail To Sway NICE On Janssen's Zytiga
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, looks set to turn down Janssen's Zytiga (abiraterone) for treating prostate cancer patients before chemotherapy is indicated. The no comes despite the firm's offer to cut the list price by 20% and pay for treatment after ten months.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.